Sahil Khanna, MBBS, MS

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.

The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Experts reflect on the barriers to utilizing fecal microbiota transplantation therapy in Clostridioides difficile infection.

The panel considers optimal therapy for recurrent CDI, particularly the role of fecal microbiota transplantation.

Centering their discussion around a patient case of CDI, experts discuss optimal therapy selection given available agents and guidelines.

Experts consider optimal approaches to administering therapy for CDI and share insight on available treatment guidelines.

Shared insight on the prevalence of recurring Clostridioides difficile infection and management strategies.

Experts review the impact that medications, antibiotic or otherwise, may have on the development of Clostridioides difficile infection.

An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.

Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.

The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.

Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.

Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.